Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - UNIGENE LABORATORIES INCex99-1.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549

FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
August 2, 2010
 

 
Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
0-16005
 
22-2328609
(State or other jurisdiction of
incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
81 Fulton Street, Boonton, New Jersey
 
07005
(Address of principal executive offices)
 
(Zip Code)
 
(973) 265-1100
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
     
o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 

 
 
Section 8 – Other Events

 
Item 8.01  Other Events.
 
On August 2, 2010, Unigene Laboratories, Inc. (the “Company”) posted on its website a letter from Ashleigh Palmer, the Company’s Chief Executive Officer and President.  A copy of the letter is attached hereto as Exhibit 99.1 and it is incorporated herein by reference.


Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
Document Description
99.1
Letter from Ashleigh Palmer
   
   
   
 

 
 
 
 
 
 
 
 

 
 
Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
UNIGENE LABORATORIES, INC.
 
     
     
 
By:
/s/ William Steinhauer
 
    William Steinhauer, Vice President of Finance  
     
     
     
Date:        August 2, 2010
     
 
 
 

 
 
 

 
 
Exhibit Index
 

Exhibit No.
Document Description
99.1
Letter from Ashleigh Palmer